This is a complete new drug review of Paxlovid, an oral antiviral agent used to treat COVID-19. A visual explanation of the drug’s mechanism of action as a protease inhibitor will be shown. The restrictions placed on this new drug due to its emergency use authorization will be outlined. Results of the EPIC-HR study will be discussed and evaluated to determine how effective Paxlovid is against Covid-19. Covered topics include contraindications, drug-drug interactions, precautions, and adverse drug reactions. This is a concise review that hopefully will provide the healthcare professional useful information.
Additional News and Links:
** July 6, 2022. FDA authorizes pharmacists to prescribe Paxlovid with certain limitations. [ Ссылка ]
** June 16, 2022: Paxlovid not shown to be beneficial in relatively healthy low risk individuals. See LA Times article: [ Ссылка ]
** May 6, 2022: Additional Paxlovid information: 1) Patient eligibility screening list (including drug drug interactions), 2) Paxlovid Locator Tool. [ Ссылка ]
==========================================================
Paxlovid official FDA News release Dec 22, 2021 [ Ссылка ]
Fact sheet for Healthcare providers (contains drug interaction chart) [ Ссылка ]
Fact sheet for patients (English) [ Ссылка ]
Fact sheet for patients (Spanish) [ Ссылка ]
Pfizer Paxlovid website [ Ссылка ]
Paxlovid FDA FAQ Dec 22, 2021 [ Ссылка ]
